| Bioactivity | iBFAR2, a BFAR inhibitor, restores the CD8+ TRM cell subset against solid tumors. iBFAR2 promotes JAK2-STAT1 association and STAT1 phosphorylation[1]. |
| Invitro | iBFAR2 在小鼠初级 CD8+ T细胞中，消除了 USP39 的泛素化，抑制了 JAK2-USP39 的相互作用，从而抑制了 JAK2 的去泛素化，进而促进了 JAK2-STAT1 的结合并增强了 STAT1 的磷酸化。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> iBFAR2 相关抗体: |
| In Vivo | iBFAR2 (ip；1, 5, 10 mg/kg；once every 2 days starting from day 7 (n = 9 mice/group)) 以剂量依赖的方式抑制 MB49 肿瘤的生长。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 353484-02-3 |
| Formula | C19H15F3N2O2 |
| Molar Mass | 360.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Siyu Pei, et al. Age-related decline in CD8+ tissue resident memory T cells compromises antitumor immunity. Nat Aging. 2024 Dec;4(12):1828-1844. |